Improving DxMultiomics, Powered by Your Choices

We're building DxMultiomics to be The Central Nexus of Biotech Intelligence. To ensure a seamless experience and continuous improvement, we utilize website analytics. These tools help us monitor site performance, understand how users navigate the platform, and identify opportunities to make your research journey more efficient. We handle this data with the utmost respect for your privacy, and you can choose what works best for you.

Calidi Biotherapeutics Gets FDA Fast Track for Novel Sarcoma Therapy CLD-201
_↗ calidibio.com
News Image

Calidi Biotherapeutics has achieved a significant milestone with the FDA Fast Track designation for its pioneering therapy, CLD-201 (SuperNova), aimed at treating soft tissue sarcoma. This designation is reserved for therapies addressing serious or life-threatening conditions with unmet medical needs, underscoring the critical demand for new sarcoma treatments. The Fast Track status will facilitate closer collaboration with the FDA, including more frequent interactions and potentially expedited review processes like Priority Review and Accelerated Approval, which could dramatically shorten the time to market for this innovative drug.

CLD-201 is a first-in-class, allogeneic adipose stem-cell loaded oncolytic vaccinia virus. This unique approach involves using adipose-derived mesenchymal stem cells (AD-MSC) as a protective carrier for the oncolytic virus. This "stem-cell loading" shields the virus from the body's immune system, allowing it to amplify within the stem cells and effectively reach and destroy tumor cells while minimizing harm to healthy tissue. This mechanism enhances the virus's potency and triggers an anti-tumor immune response, as demonstrated in preclinical studies.

Following the Investigational New Drug (IND) clearance in April 2025, Calidi plans to initiate a Phase 1, first-in-human, open-label, multicenter trial to assess the safety, tolerability, and preliminary efficacy of CLD-201. While the primary focus is soft tissue sarcoma, the trial will also investigate its potential in other aggressive solid tumors, including triple-negative breast cancer and head and neck squamous cell carcinoma, highlighting the broad applicability of Calidi's proprietary Redtail platform. This platform, refined over a decade, focuses on designing viral vectors that can evade immune detection, enabling systemic delivery of genetic medicines to metastatic sites of disease. The Fast Track designation, combined with the IND clearance, represents a crucial step forward for Calidi in bringing this promising therapy to patients with high unmet medical needs.

Log In
Sign Up